January 18, 2022
Life Sciences
  • A small study of Israeli medical workers found that a fourth dose of the Pfizer-BioNTechCOVID-19 vaccine wasn’t enough to prevent infection with the Omicron variant. However, the extra shot did raise antibody levels. The trial’s lead researcher said the findings suggest that rolling out extra doses to the most vulnerable could help bolster protection, but that they didn’t support offering the shots to the broader population. (Article here)